Date: 2012-11-14
Type of information: Initiation of the trial
phase:
Announcement: initiation of the trial
Company: DBV Technologie (France)
Product: Viaskin HDM
Action mechanism:
Disease: house dust mites allergy
Therapeutic area: Allergic diseases - Immune diseases
Country:
Trial details:
Latest
news: DBV Technologies has announced the launch of its third Viaskin programme in the treatment of house dust mites allergy. This programme will be carried out in the framework of ImmunAVia, a €16.4 million project supported and partly financed by the public funds provided by the Industrial Strategic Innovation program (ISI) of Oseo. ImmunAvia is a multidimensional project in the field of diagnostics and treatment of house dust mites allergy led by DBV and regrouping Genclis, a French biotech company specialized in recombinant proteins and CHU of Lyon (Hospices civils and university Claude Bernard Lyon1) in the field of paediatric clinical development.
DBV Technologies will receive from OSEO-ISI up to €5.1 million in milestones (composed of subsidies and advance payments) for the development of Viaskin HDM up to proof of concept (end of phase II) out of a total grant of €7.6 million for the full ImmunAvia project. Approximately 30% DBV’s milestones will be paid upfront early 2013. The development of Viaskin HDM will therefore be positive to DBV in terms of cash burn in 2013 and 2014. Viaskin HDM preclinical studies will start in the first half of 2013.
